Trials / Terminated
TerminatedNCT04171700
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- pharmaand GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rucaparib | Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID). |
Timeline
- Start date
- 2020-01-16
- Primary completion
- 2022-06-08
- Completion
- 2022-07-15
- First posted
- 2019-11-21
- Last updated
- 2023-10-02
- Results posted
- 2023-10-02
Locations
19 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04171700. Inclusion in this directory is not an endorsement.